Protocol Ledger

NCT03937141 · Phase II · TERMINATED

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Interventional Phase II clinical trial protocol NCT03937141 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-26 Enrollment: 16 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03937141
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03937141
Protocol FieldVerified Registry Value
NCT IdentifierNCT03937141
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment16 participants (ACTUAL)
Registered Start Date2019-08-26
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI